TradingBlock Appoints Veteran Technology Executive as Director of Networking
Gustafson is responsible for designing, building and overseeing TradingBlock's network infrastructure, a critical role as network performance directly impacts trade execution speed, reliability and security.
"David's expertise in building and optimizing high-performance trading networks will strengthen the foundation of our platform and ensure we continue to deliver powerful, fully customizable trading solutions to retail and institutional traders," said TradingBlock President and CEO
Gustafson has held leadership roles at Jump Trading, Chopper Trading, TransMarket Group and Calyon Financial. Throughout his career, he has architected and deployed global networks, pioneered low-latency trading connectivity and advanced enterprise IT and security operations across
"I am thrilled to join TradingBlock because of its commitment to empowering traders with innovative technology and reliable infrastructure," Gustafson said. "I look forward to helping build a platform that not only performs at the highest level but also positions TradingBlock for long-term growth and client success."
Gustafson holds an MBA with honors in Entrepreneurship and Economics from the University of Chicago Booth School of Business and a B.S. in Organizational Behavior and Computer Science from Northwestern University.
About TradingBlock
TradingBlock is a FINRA-member broker-dealer and comprehensive trading technology platform and brokerage solutions provider launched in 2003 and headquartered in
Media Contact
[email protected]
424-317-4868
View original content to download multimedia:https://www.prnewswire.com/news-releases/tradingblock-appoints-veteran-technology-executive-as-director-of-networking-302557103.html
SOURCE TradingBlock
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
- KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026
- Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Calyon Securities, Hedge FundsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share